Pharmacogenomic overlap between antidepressant treatment response in major depression & antidepressant associated treatment emergent mania in bipolar disorder.

Autor: Nuñez NA; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Coombes BJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Beaupre LM; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Ozerdem A; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Resendez MG; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.; Department of Psychiatry, Universidad Autónoma de Nuevo León, Monterrey, México., Romo-Nava F; Lindner Center of HOPE/University of Cincinnati, Cincinnati, OH, USA., Bond DJ; Department of Psychiatry & Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA., Veldic M; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Singh B; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Moore KM; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Betcher HK; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Kung S; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Prieto ML; Department of Psychiatry, Faculty of Medicine, Universidad de Los Andes, Santiago, Chile., Fuentes M; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Ercis M; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Miola A; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Sanchez Ruiz JA; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA., Jenkins G; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Batzler A; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Leung JG; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA., Cuellar-Barboza A; Department of Psychiatry, Universidad Autónoma de Nuevo León, Monterrey, México., Tye SJ; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.; Queensland Brain Institute, The University of Queensland, St. Lucia, QLD, Australia., McElroy SL; Lindner Center of HOPE/University of Cincinnati, Cincinnati, OH, USA., Biernacka JM; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Frye MA; Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA. mfrye@mayo.edu.
Jazyk: angličtina
Zdroj: Translational psychiatry [Transl Psychiatry] 2024 Feb 13; Vol. 14 (1), pp. 93. Date of Electronic Publication: 2024 Feb 13.
DOI: 10.1038/s41398-024-02798-y
Abstrakt: There is increasing interest in individualizing treatment selection for more than 25 regulatory approved treatments for major depressive disorder (MDD). Despite an inconclusive efficacy evidence base, antidepressants (ADs) are prescribed for the depressive phase of bipolar disorder (BD) with oftentimes, an inadequate treatment response and or clinical concern for mood destabilization. This study explored the relationship between antidepressant response in MDD and antidepressant-associated treatment emergent mania (TEM) in BD. We conducted a genome-wide association study (GWAS) and polygenic score analysis of TEM and tested its association in a subset of BD-type I patients treated with SSRIs or SNRIs. Our results did not identify any genome-wide significant variants although, we found that a higher polygenic score (PGS) for antidepressant response in MDD was associated with higher odds of TEM in BD. Future studies with larger transdiagnostic depressed cohorts treated with antidepressants are encouraged to identify a neurobiological mechanism associated with a spectrum of depression improvement from response to emergent mania.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: